Royal Bank of Canada
OTLK icon

Royal Bank of Canada’s Outlook Therapeutics OTLK Stock Holding History

Royal Bank of Canada’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
85
-602
-88% -$260 ﹤0.01% 7526
2025
Q4 		$1K Sell
687
-4,106
-86% -$6.56K ﹤0.01% 7028
2025
Q3 		$5K Sell
4,793
-19,819
-81% -$34.3K ﹤0.01% 6708
2025
Q2 		$39K Buy
24,612
+24,102
+4,726% +$38.4K ﹤0.01% 6018
2025
Q1 		$0 Sell
510
-933
-65% -$1.64K ﹤0.01% 7126
2024
Q4 		$2K Sell
1,443
-1,204
-45% -$4.95K ﹤0.01% 6723
2024
Q3 		$14K Buy
2,647
+1,767
+201% +$12.9K ﹤0.01% 6232
2024
Q2 		$6K Sell
880
-9,744
-92% -$78.2K ﹤0.01% 6495
2024
Q1 		$127K Buy
10,624
+8,010
+306% +$64.8K ﹤0.01% 5050
2023
Q4 		$20K Buy
2,614
+1,503
+135% +$12.7K ﹤0.01% 6314
2023
Q3 		$5K Buy
1,111
+514
+86% +$11.4K ﹤0.01% 6615
2023
Q2 		$21K Buy
597
+100
+20% +$2.73K ﹤0.01% 6192
2023
Q1 		$10K Sell
497
-399
-45% -$8.93K ﹤0.01% 6318
2022
Q4 		$19K Buy
896
+824
+1,144% +$17.9K ﹤0.01% 6325
2022
Q3 		$2K Buy
72
+38
+112% +$884 ﹤0.01% 7049
2022
Q2 		$1K Sell
34
-316
-90% -$9.09K ﹤0.01% 7172
2022
Q1 		$12K Sell
350
-677
-66% -$21.1K ﹤0.01% 6881
2021
Q4 		$28K Buy
1,027
+486
+90% +$17.3K ﹤0.01% 6646
2021
Q3 		$23K Sell
541
-1,826
-77% -$88.1K ﹤0.01% 6633
2021
Q2 		$118K Buy
2,367
+2,067
+689% +$95.9K ﹤0.01% 5498
2021
Q1 		$14K Buy
+300
New +$11.5K ﹤0.01% 6642
2020
Q3 		– Sell
-17
Closed – – 6841
2020
Q2 		$0 Hold
17
– – ﹤0.01% 6827
2020
Q1 		$0 Hold
17
– – ﹤0.01% 6933
2019
Q4 		$0 Buy
+17
New +$396 ﹤0.01% 7041
2018
Q1 		– Hold
0
– – – 6672
2017
Q4 		– Hold
0
– – – 6783
2017
Q3 		– Hold
0
– – – 6901

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Royal Bank of Canada's OTLK Position: Q1 2026 in Review

Royal Bank of Canada reduced its Outlook Therapeutics (OTLK) stake by 88% in Q1 2026, selling an estimated $260 and leaving 85 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7526.

Royal Bank of Canada first reported a position in OTLK in Q4 2019 and has held it in 24 quarters since. The position peaked at $127K in Q1 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Royal Bank of Canada held 85 shares of Outlook Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 602 Outlook Therapeutics shares in Q1 2026, an estimated $260.
  • Outlook Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7526 holding.
  • Royal Bank of Canada first reported a position in Outlook Therapeutics in Q4 2019 and has held it in 24 quarters since.
  • Royal Bank of Canada's Outlook Therapeutics position peaked at $127K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.